Pfizer-Wyeth Merger and Meetings

The Pfizer-Wyeth merger will mean changes for its meetings department. What they may be, however, is still up in the air.

Pfizer completed its $67 billion acquisition of Wyeth Pharmaceuticals last fall, just one in a string of recent mergers and acquisitions in the pharma industry. When asked how the two meetings departments would be affected and how procurement and sourcing would be handled, Joan Campion, a spokeswoman for Pfizer, declined to get specific: “I can tell you that Pfizer is continuing to evaluate its global workforce, which includes our medical meetings group, to determine how best to support

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.